Guidance for the Interpretation of Long-Acting Cabotegravir and Rilpivirine Concentrations Based on Real-World Therapeutic Drug Monitoring Data and Documented Failures

被引：9
|
作者：
Thoueille, Paul [1 ,2 ]
Cavassini, Matthias [2 ,3 ]
Guidi, Monia [1 ,2 ,4 ,5 ]
Buclin, Thierry [1 ,2 ]
Girardin, Francois R. [1 ,2 ]
Decosterd, Laurent A. [1 ,2 ]
Marzolini, Catia [1 ,6 ,7 ,8 ,9 ]
机构：
[1] Lausanne Univ Hosp, Dept Lab Med & Pathol, Serv & Lab Clin Pharmacol, Lausanne, Switzerland
[2] Univ Lausanne, Lausanne, Switzerland
[3] Lausanne Univ Hosp, Dept Med, Serv Infect Dis, Lausanne, Switzerland
[4] Lausanne Univ Hosp, Ctr Res & Innovat Clin Pharmaceut Sci, Lausanne, Switzerland
[5] Univ Lausanne, Univ Geneva, Inst Pharmaceut Sci Western Switzerland, Geneva, Switzerland
[6] Univ Basel, Univ Hosp Basel, Div Infect Dis & Hosp Epidemiol, Basel, Switzerland
[7] Univ Liverpool, Inst Translat Med, Dept Mol & Clin Pharmacol, Liverpool, England
[8] Lausanne Univ Hosp, Dept Lab Med & Pathol, Serv & Lab Clin Pharmacol, Rue Bugnon 17, Lausanne, Switzerland
[9] Univ Lausanne, Rue Bugnon 17, Lausanne, Switzerland
来源：
OPEN FORUM INFECTIOUS DISEASES | 2024年 / 11卷 / 02期
基金：
瑞士国家科学基金会;
关键词：
cabotegravir; guidance; long-acting; rilpivirine; TDM; ADULTS;
D O I：
10.1093/ofid/ofae023
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The interpretation of long-acting cabotegravir and rilpivirine concentrations is complicated by the lack of consensus on the threshold to consider. Building on real-world therapeutic drug monitoring data and documented virologic failures, this article provides a reappraisal of the existing thresholds and guidance for the interpretation of cabotegravir and rilpivirine concentrations. There is no established threshold for the interpretation of long-acting cabotegravir/rilpivirine concentrations. Building on real-world TDM data and documented virologic failures, this article provides a reappraisal of the existing thresholds, and guidance for the interpretation of cabotegravir and rilpivirine concentrations.
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Therapeutic Drug Monitoring of Long-Acting Rilpivirine and Cabotegravir for Treatment of HIV-1 Infection-A Case Series of Five Patients With One Virologic Failure After Development of Two-Class Resistance
    Gerstenberg, Jacob
    Klinker, Hartwig
    Baier, Michael
    von Braun, Amrei
    Seybold, Ulrich
    Helbig, Carlotta
    Daeumer, Martin
    Korn, Klaus
    Stephan, Christoph
    Schleenvoigt, Benjamin T.
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (09):
  • [22] Six-month outcomes of every 2-months long-acting cabotegravir and rilpivirine in a real-world setting: effectiveness, adherence to injections and patient-reported outcomes from PLWHIV in the German CARLOS cohort
    Borch, J.
    Scherzer, J.
    Jonsson-Oldenbuettel, C.
    Weinberg, G.
    Wyen, C.
    Rodriguez, E.
    Scholten, S.
    Dakhia, S.
    Dymek, K.
    Westermayer, B.
    Bernhardt, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 20 - 21
  • [23] Real-world clinical outcomes of HIV-1 virologically suppressed adults on bictegravir/emtricitabine/tenofovir alafenamide who switched to long-acting intramuscular cabotegravir plus rilpivirine at 12, 24, and 48-weeks
    Nasser, K.
    Valentin, A. -M.
    Ramgopal, M.
    HIV MEDICINE, 2023, 24 : 161 - 162
  • [24] Therapeutic Drug Monitoring of Certolizumab Pegol: Can Real-World Data Translate to Clinical Practice?
    Battat, Robert
    CROHNS & COLITIS 360, 2021, 3 (03)
  • [25] Drug-induced hypokalemia: an analytical study based on real-world drug monitoring data
    Song, Bo
    Liu, Liheng
    Dong, Shichao
    Wang, Shanshan
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [26] Long-acting antiretroviral therapy effectiveness and patient satisfaction using patient questionnaires: data from a real-world setting
    Konishi, Keiji
    Onozuka, Daisuke
    Okubo, Moeka
    Kasamatsu, Yu
    Kutsuna, Satoshi
    Shirano, Michinori
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
  • [27] Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: Data from a real-world setting
    Suttorp, Meinolf
    Sembill, Stephanie
    Lensker, Phyllis
    Hildebrand, Verena
    Schirmer, Elke
    Karow, Axel
    Krumbholz, Manuela
    Rauh, Manfred
    Metzler, Markus
    BRITISH JOURNAL OF HAEMATOLOGY, 2025,
  • [28] Results at month 7 of CABO-CHANCE study: real-world evidence (RWE) on the use of intramuscular cabotegravir plus rilpivirine long-acting (CAB plus RPV LA) dosed every 2 months in viral suppressed people with HIV (PWH)
    Tenorio, Carmen Hidalgo
    Aguilera-Garcia, Maria
    Santos, Ignacio De Los
    Vinuesa, David
    Omar, Mohamed
    Lirola, Ana Lopez
    Bernal, Enrique
    Martinez, Onofre Juan
    Romero, Alberto
    Sorni, Patricia
    Lopez, Teresa
    Cardenas, Salvador Lopez
    Moreno, Santiago
    Conde, Isabel San Joaquin
    Blanco, Jose Ramon
    Garcia-Vallecillos, Coral
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 108 - 109
  • [29] Therapeutic Drug Monitoring for Dose Optimization of Infliximab in Patients With Inflammatory Bowel Disease: An Analysis of Canadian Real-World Data
    Sealey, David C.
    Ho, Kai Fai
    Zhou, Z. Christina
    Clark, Michael
    Feagan, Brian G.
    Panaccione, Remo
    Steinhart, A. Hillary
    Bolshtyansky, Elena
    Williamson, Martin
    Afif, Waqqas
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2025, 2025 (01)
  • [30] Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone - Evidence from a routine therapeutic drug monitoring service
    Castberg, I
    Spigset, A
    THERAPEUTIC DRUG MONITORING, 2005, 27 (01) : 103 - 106
12345